Search

Displaying results 1461 - 1470 of 7687 in total
  1. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

    Synonyms: N-D-Glucosyl-(2)-N'-nitrosomethylurea, N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
  2. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.

  3. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562] … Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs).

  4. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

  5. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strain...

  6. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  7. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. … Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.

  8. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively

  9. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). … The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G).

  10. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45196] It was granted FDA approval under the brand name Lenmeldy in March 2024.[L50256] … [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic